MERRIMACK PHARMACEUTICALS INC financial data

Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2024 - 15 May 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1258% % -64%
Debt-to-equity 8.6% % 190%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14,531,760 shares 1.9%
Common Stock, Shares, Outstanding 14,532,000 shares 1.9%
Common Stock, Value, Issued $1,345,000 USD 0.15%
Weighted Average Number of Shares Outstanding, Basic 14,452,000 shares 1.4%
Weighted Average Number of Shares Outstanding, Diluted 14,452,000 shares 1.4%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $2,259,000 USD 3.5%
Operating Income (Loss) $2,259,000 USD -11%
Nonoperating Income (Expense) $925,000 USD 32%
Earnings Per Share, Basic 14 USD/shares
Earnings Per Share, Diluted 14 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $234,160,000 USD 1107%
Cash, Cash Equivalents, and Short-term Investments $244,100,000 USD 1158%
Assets, Current $244,319,000 USD 1145%
Other Assets, Noncurrent $3,000 USD -57%
Assets $244,322,000 USD 1144%
Accounts Payable, Current $168,000 USD 89%
Accrued Liabilities, Current $161,000 USD 18%
Liabilities, Current $22,672,000 USD 4797%
Liabilities $22,672,000 USD 4797%
Retained Earnings (Accumulated Deficit) $347,447,000 USD 37%
Stockholders' Equity Attributable to Parent $221,650,000 USD 1056%
Liabilities and Equity $244,322,000 USD 1144%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,314,000 USD -269%
Net Cash Provided by (Used in) Financing Activities $1,485,000 USD 730%
Net Cash Provided by (Used in) Investing Activities $228,000,000 USD 163929%
Common Stock, Shares Authorized 30,000,000 shares 0%
Common Stock, Shares, Issued 14,532,000 shares 1.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $228,171,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $234,160,000 USD 1107%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $200,460,000 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%